증례 : 신장 ; 신이식 환자의 항체매개성 거부반응에서 Bortezomib으로 치료한 1예 = Case Reports : Nephrology ; Proteasome-Inhibitor-Based Primary Therapy for Antibody-Mediated Rejection in a Renal Transplant Recipient

국문 초록 (Abstract)

공여자 특이 항체는 이식신 부전의 주요 원인이 되며 이를 효과적으로 제거하는 것은 이전의 치료 방법을 통해서는 충분히 달성되지 못했다. 저자들은 39세 여자 환자로 신기능저하로 입원하여 신조직 검사에서 C4d 미만성 양성 소견 및 혈중 공여자 특이 항체의 존재로 항체 매개 거부 반응을 진단받았고, 프로테아좀 억제제인 bortezomib을 통해 조직학적소견의 호전 및 혈중 공여자 특이 항체의 감소와 이식신 기능회복을 가져온 증례를 경험하였기에 이를 보고한다.

다국어 초록 (Multilingual Abstract)

Donor-specific anti-human leukocyte antigen antibodies (DSA) following kidney transplantation predict the evolution of humoral rejection and reduced graft survival. Rapid, complete elimination of DSA during antibody-mediated rejection (AMR) is rarely achieved with traditional antihumoral therapies. We report the case of a 39-year-old female who was admitted for increasing azotemia and diagnosed with AMR based on diffusely positive histological changes on C4d immunostaining. In this case, bortezomib reversed the histological changes and induced a reduction in DSA. Proteasome-inhibitor-based combination therapy is a potential means for rapid DSA elimination in antibody-mediated rejection in renal transplant recipients. (Korean J Med 2011;81:780-785)

참고문헌 (Reference)

1 Shah A, "Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin" 77 : 1399-1405, 2004

2 Ramos EJ, "The effect of desensitization protocols on human splenic B-cell populations in vivo" 7 : 402-407, 2007

3 Kraus ES, "Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations" 9 : 1826-1834, 2009

4 Everly MJ, "Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss" 9 : 1063-1071, 2009

5 Nencioni A, "Proteasome inhibitors: antitumor effects and beyond" 21 : 30-36, 2007

6 Walsh RC, "Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection" 89 : 277-284, 2010

7 Worthington JE, "Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome" 75 : 1034-1040, 2003

8 Scornik JC, "Posttransplant antidonor antibodies and graft rejection: evaluation by two-color flow cytometry" 47 : 287-290, 1989

9 Kaposztas Z, "Impact of rituximab therapy for treatment of acute humoral rejection" 23 : 63-73, 2009

10 Terasaki PI, "Humoral theory of transplantation" 3 : 665-673, 2003

11 Terasaki PI, "Human leukocyte antigen antibodies and chronic rejection: from association to causation" 86 : 377-383, 2008

12 Idica A, "Elimination of posttransplant donor-specific HLA antibodies with bortezomib" Clin Transpl 229-239, 2008

13 Everly MJ, "Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection" 86 : 1754-1761, 2008

14 Sberro-Soussan R, "Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies" 10 : 681-686, 2010

15 Sis B, "Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups" 10 : 464-471, 2010

16 Lee PC, "All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies" 74 : 1192-1194, 2002

17 Zarkhin V, "A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation" 8 : 2607-2617, 2008